{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:06:05Z","timestamp":1794557165820,"version":"4.9.1"},"reference-count":158,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117134","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T07:25:29Z","timestamp":1784877929000},"page":"117134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Advancing chimeric antigen receptor T-cell therapy frontiers in glioblastoma: Navigating the current landscape from clinical hurdles to breakthrough strategies"],"prefix":"10.1016","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7539-8423","authenticated-orcid":false,"given":"Raju Kumar","family":"Sarma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6060-9010","authenticated-orcid":false,"given":"Parthajyoti","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5451-5293","authenticated-orcid":false,"given":"Paragmoni","family":"Bora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8153-8942","authenticated-orcid":false,"given":"Purbajit","family":"Chetia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2148-2331","authenticated-orcid":false,"given":"Asis","family":"Bala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117134_bb0005","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-025-04247-z","article-title":"Clusterin-mediated polarization of M2 macrophages: a mechanism of temozolomide resistance in glioblastoma stem cells","volume":"16","author":"Wen","year":"2025","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.intimp.2026.117134_bb0010","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s40478-022-01422-8","article-title":"Glioblastoma CD105+ cells define a SOX2- cancer stem cell-like subpopulation in the pre-invasive niche","volume":"10","author":"Li","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.intimp.2026.117134_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci14070687","article-title":"Neuroinflammation in glioblastoma: Progress and perspectives","volume":"14","author":"Li","year":"2024","journal-title":"Brain Sci."},{"key":"10.1016\/j.intimp.2026.117134_bb0020","doi-asserted-by":"crossref","DOI":"10.1590\/1678-4324-2025240161","article-title":"Linalool alleviates oxidative stress and inflammatory markers in rats with CFA-induced rheumatoid arthritis","volume":"68","author":"Chutia","year":"2025","journal-title":"Braz. Arch. Biol. Technol."},{"key":"10.1016\/j.intimp.2026.117134_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/cells12030374","article-title":"Defining a correlative transcriptional signature associated with bulk histone H3 acetylation levels in adult glioblastomas","volume":"12","author":"Herv\u00e1s-Corpi\u00f3n","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.117134_bb0030","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-025-04222-w","article-title":"CAR-T cells immunotherapy in the treatment of glioblastoma","volume":"74","author":"Kr\u00f3likowska","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2026.117134_bb0035","first-page":"1","article-title":"Unraveling the immunosuppressive microenvironment of glioblastoma and advancements in treatment","volume":"16","author":"Jiang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117134_bb0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.15584\/ejcem.2024.1.12","article-title":"Selegiline modulates inflammatory indicators in RAW 264.7 macrophages and LPS-aggravated CFA-induced rheumatoid arthritis in rats","volume":"22","author":"Ahmed","year":"2024","journal-title":"Eur. J. Clin. Exp. Med."},{"key":"10.1016\/j.intimp.2026.117134_bb0045","doi-asserted-by":"crossref","first-page":"7090","DOI":"10.7150\/thno.114257","article-title":"Overcoming barriers in glioblastoma: the potential of CAR T cell immunotherapy","volume":"15","author":"Ijaz","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2026.117134_bb0050","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-025-06475-6","article-title":"Efficacy of MET-targeting CAR T cells against glioblastoma patient-derived xenograft models","volume":"23","author":"Qin","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117134_bb0055","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.117134_bb0060","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Dejenie","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2026.117134_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01850","article-title":"Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications","volume":"8","author":"Mirzaei","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117134_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T therapy technologies: has the promise been met?","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.117134_bb0075","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-024-03479-y","article-title":"Recent updates on allogeneic CAR-T cells in hematological malignancies","volume":"24","author":"Mansoori","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.intimp.2026.117134_bb0080","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-025-01820-x","article-title":"Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer","volume":"25","author":"Sueangoen","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.intimp.2026.117134_bb0085","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01737-8","article-title":"Recent advances in universal chimeric antigen receptor T cell therapy","volume":"18","author":"Jiang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.117134_bb0090","doi-asserted-by":"crossref","unstructured":"S. Rafii, D. Mukherji, A.S. Komaranchath, C. Khalil, F. Iqbal, S.I. Abdelwahab, A. Abyad, A.Y. Abuhelwa, L. Gandikota, H.O. Al-Shamsi, Advancing CAR T-cell therapy in solid tumors: current landscape and future directions, Cancers (Basel) 17 (2025) 1\u201352. doi:https:\/\/doi.org\/10.3390\/cancers17172898.","DOI":"10.3390\/cancers17172898"},{"key":"10.1016\/j.intimp.2026.117134_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106529","article-title":"Design of diversified chimeric antigen receptors through rational module recombination","volume":"26","author":"Si","year":"2023","journal-title":"IScience"},{"key":"10.1016\/j.intimp.2026.117134_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2025.1664403","article-title":"Non-signaling but all important: how the linker, hinge, and transmembrane domains in the CAR hold it all together","volume":"16","author":"Bernard","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117134_bb0105","first-page":"1","article-title":"The impact of CD3\u03b6 ITAM multiplicity and sequence on CAR T-cell survival and function","volume":"15","author":"Majumdar","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117134_bb0110","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-025-06857-w","article-title":"Discordant CAR-T cell signaling: implications of divergence from physiological T cell activation","volume":"23","author":"Gonzalez-Garcia","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117134_bb0115","doi-asserted-by":"crossref","first-page":"8595","DOI":"10.1093\/nar\/gkae549","article-title":"Logical regulation of endogenous gene expression using programmable, multi-input processing CRISPR guide RNAs","volume":"52","author":"Kang","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2026.117134_bb0120","doi-asserted-by":"crossref","DOI":"10.1186\/s13036-024-00459-8","article-title":"Construction of multilayered gene circuits using de-novo-designed synthetic transcriptional regulators in cell-free systems","volume":"18","author":"Zhao","year":"2024","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.intimp.2026.117134_bb0125","first-page":"406","article-title":"Design and engineering of logic genetic-enzymatic gates based on the activity of the human CYP2C9 enzyme in permeabilized Saccharomyces cerevisiae cells, synth. Syst","volume":"9","author":"Ashraf","year":"2024","journal-title":"Biotechnol"},{"key":"10.1016\/j.intimp.2026.117134_bb0130","article-title":"CAR T-cell therapies: a comparison of strategies for glioblastoma multiforme treatment","volume":"9","author":"Sundar","year":"2025","journal-title":"J. High Sch. Sci."},{"key":"10.1016\/j.intimp.2026.117134_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-024-00679-6","article-title":"Advances in CAR-T therapy for central nervous system tumors","volume":"12","author":"Zhou","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.intimp.2026.117134_bb0140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2026.117134_bb0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/cancers16010039","article-title":"Evolving CAR-T-cell therapy for cancer treatment: from scientific discovery to cures","volume":"16","author":"Majumder","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117134_bb0150","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.ymthe.2025.03.004","article-title":"CAR T cell therapy for glioblastoma: a review of the first decade of clinical trials","volume":"33","author":"Begley","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.117134_bb0155","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/hemoncstem.HEMONCSTEM-D-24-00040","article-title":"A critical review of CAR-T therapies for glioblastoma: what\u2019s wrong with the current attempts?","volume":"18","author":"Belokon","year":"2025","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"10.1016\/j.intimp.2026.117134_bb0160","first-page":"1","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117134_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.114609","article-title":"CAR-T cell therapies are coming after glioblastoma: an overview of early phase clinical trials and future perspectives","volume":"29","author":"Mariniello","year":"2026","journal-title":"IScience"},{"key":"10.1016\/j.intimp.2026.117134_bb0170","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117134_bb0175","first-page":"4062","article-title":"Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2016"},{"key":"10.1016\/j.intimp.2026.117134_bb0180","series-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","author":"Rourke","year":"2017"},{"key":"10.1016\/j.intimp.2026.117134_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/S1525-0016(16)33624-3","article-title":"20. Carboxylesterase-secreting neural stem cells increase efficacy of irinotecan in orthotopic glioma models: translation toward the clinic","volume":"23","author":"Ghoda","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.117134_bb0190","series-title":"CAR-T cell products in solid tumors: progress, challenges, and strategies","first-page":"1","author":"Qian","year":"2024"},{"key":"10.1016\/j.intimp.2026.117134_bb0195","first-page":"126","article-title":"Pilot trial of adoptive transfer of chimeric antigen receptor transduced T cells targeting EGFRvIII in patients with glioblastoma","volume":"42","author":"Goff","year":"2020"},{"key":"10.1016\/j.intimp.2026.117134_bb0200","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.intimp.2026.117134_bb0205","article-title":"EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma","volume":"9","author":"Miao","year":"2014"},{"key":"10.1016\/j.intimp.2026.117134_bb0210","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.117134_bb0215","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117134_bb0220","first-page":"1290","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024"},{"key":"10.1016\/j.intimp.2026.117134_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102302","article-title":"Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: interim clinical experience demonstrating feasibility and safety","volume":"6","author":"Barish","year":"2025","journal-title":"Cell Reports Med."},{"key":"10.1016\/j.intimp.2026.117134_bb0230","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/cancers15051414","article-title":"CAR T cell therapy in glioblastoma: overcoming challenges related to antigen expression","volume":"15","author":"Luksik","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117134_bb0235","doi-asserted-by":"crossref","first-page":"viii90","DOI":"10.1093\/neuonc\/noae165.0354","article-title":"CTIM-21. First-in-human phase I clinical trial using 8R-70CAR T cells for newly diagnosed adult glioblastoma","volume":"26","author":"Ghiaseddin","year":"2024","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.intimp.2026.117134_bb0240","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1200\/JCO.2025.43.16_suppl.2018","article-title":"A phase 1 study of B7H3 CAR-T cells administered intracranially in recurrent glioblastoma","volume":"43","author":"Li","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117134_bb0270","article-title":"CAR-T cell therapy: advances in digestive system malignant tumors","volume":"32","author":"Xu","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.intimp.2026.117134_bb0275","series-title":"CAR-T cell therapy in brain malignancies : obstacles in the face of cellular traf fi cking and persistence","first-page":"1","author":"Yaacoub","year":"2025"},{"key":"10.1016\/j.intimp.2026.117134_bb0280","series-title":"Phase 1b multicenter study to evaluate CHM 1101 in patients with recurrent or progressive","author":"Litten","year":"2023"},{"key":"10.1016\/j.intimp.2026.117134_bb0285","series-title":"EGFR as a potent CAR T target in triple negative breast cancer brain metastases","first-page":"57","volume":"197","author":"Subham","year":"2024"},{"key":"10.1016\/j.intimp.2026.117134_bb0290","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41698-021-00233-9","article-title":"GD2 CAR T cells against human glioblastoma","volume":"5","author":"Prapa","year":"2021","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.intimp.2026.117134_bb0295","article-title":"CAR-T cell therapy for the treatment of adult high-grade gliomas","volume":"8","author":"Park","year":"2024","journal-title":"Npj Precis. Oncol."},{"key":"10.1016\/j.intimp.2026.117134_bb0300","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.3390\/cancers15235652","article-title":"Chimeric antigen receptor T-cell therapy for glioblastoma","volume":"15","author":"Ma","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117134_bb0305","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.2147\/IJGM.S418837","article-title":"Insight into the Progress in CAR-T cell therapy and combination with other therapies for glioblastoma","volume":"16","author":"Liang","year":"2023","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.intimp.2026.117134_bb0310","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1097\/MS9.0000000000003607","article-title":"CAR-T cell therapy for glioblastoma: advances, challenges, and future directions","volume":"87","author":"Czy\u017cewski","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.intimp.2026.117134_bb0315","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2024.42.16_suppl.2062","article-title":"Safety and efficacy of B7-H3 targeting CAR-T cell therapy for patients with recurrent GBM","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117134_bb0320","article-title":"Chimeric antigen receptor (CAR)-T-cell therapy for glioblastoma: what can we learn from the early clinical trials? A systematic review","volume":"7","author":"Chan","year":"2025","journal-title":"Neuro-Oncol. Adv."},{"key":"10.1016\/j.intimp.2026.117134_bb0325","series-title":"CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives","author":"Epperly","year":"2024"},{"key":"10.1016\/j.intimp.2026.117134_bb0330","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1433432","article-title":"\u201cOff-the-shelf\u201d allogeneic chimeric antigen receptor T-cell therapy for B-cell malignancies: current clinical evidence and challenges","volume":"14","author":"Mohty","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.117134_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640082","article-title":"Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma","volume":"12","author":"Mart\u00ednez Bedoya","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117134_bb0340","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1016\/j.ymthe.2025.09.026","article-title":"Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety","volume":"33","author":"Li","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.117134_bb0345","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","volume":"43","author":"Li","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2026.117134_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100804","article-title":"Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.intimp.2026.117134_bb0355","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2517786122","article-title":"Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell-engineered mesothelin-redirected CAR-NKT cells","volume":"122","author":"Li","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2026.117134_bb0360","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.3390\/cancers15245852","article-title":"Cytokine modification of adoptive chimeric antigen receptor immunotherapy for glioblastoma","volume":"15","author":"Pawlowski","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117134_bb0365","article-title":"Emerging trends in clinical allogeneic CAR cell therapy","author":"Li","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.intimp.2026.117134_bb0370","doi-asserted-by":"crossref","first-page":"viii248","DOI":"10.1093\/neuonc\/noae165.0982","article-title":"EXTH-51. Enhancing glioblastoma treatment: allogeneic CAR-T cells overcomes functional deficits of patient-derived autologous products","volume":"26","author":"Shaikh","year":"2024","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.intimp.2026.117134_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2025.1557157","article-title":"Allogeneic CART progress: platforms, current progress and limitations","volume":"16","author":"Shokati","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117134_bb0380","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41573-022-00476-6","article-title":"Engineering the next generation of cell-based therapeutics","volume":"21","author":"Bashor","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2026.117134_bb0385","series-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","author":"Abou-el-enein","year":"2021"},{"key":"10.1016\/j.intimp.2026.117134_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-023-00435-w","article-title":"Current approaches to develop \u201coff-the-shelf\u201d chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review","volume":"12","author":"Aparicio","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.117134_bb0395","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.intimp.2026.117134_bb0400","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 Universal trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117134_bb0405","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-024-01639-1","article-title":"Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO congress","volume":"17","author":"Huang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.117134_bb0420","author":"P. University"},{"key":"10.1016\/j.intimp.2026.117134_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2023.1142597","article-title":"The peculiar challenge of bringing CAR-T cells into the brain: perspectives in the clinical application to the treatment of pediatric central nervous system tumors","volume":"14","author":"Del Baldo","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117134_bb0430","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.7150\/ijbs.108036","article-title":"From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapy","volume":"21","author":"Wang","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.intimp.2026.117134_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-020-00192-6","article-title":"Characterization of novel dual tandem CD19\/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma","volume":"8","author":"Kang","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.intimp.2026.117134_bb0440","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009403","article-title":"EphA3 CAR T cells are effective against glioblastoma in preclinical models","volume":"12","author":"Martins","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117134_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-025-00755-5","article-title":"Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs","volume":"13","author":"Guo","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.intimp.2026.117134_bb0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2025.1546172","article-title":"Tandem CAR-T cell therapy: recent advances and current challenges","volume":"16","author":"G\u00f3mez-Melero","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117134_bb0455","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202504973","article-title":"A review on microwave-assisted synthesis of fused N-containing bioactive heterocyclic molecules","volume":"11","author":"Sarma","year":"2026","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.intimp.2026.117134_bb0460","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.ymthe.2025.07.044","article-title":"Computational structural optimization enhances IL13R\u03b12 \u2013 B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape","volume":"33","author":"Meehl","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.117134_bb0465","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.omto.2022.02.012","article-title":"A novel TanCAR targeting IL13R\u03b12 and EphA2 for enhanced glioblastoma therapy","volume":"24","author":"Muhammad","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.intimp.2026.117134_bb0470","first-page":"506","article-title":"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma, neuro","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Oncol"},{"key":"10.1016\/j.intimp.2026.117134_bb0475","article-title":"Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma","volume":"5","author":"Schmidts","year":"2023","journal-title":"Neuro-Oncol. Adv."},{"key":"10.1016\/j.intimp.2026.117134_bb0480","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/neuonc\/noae126","article-title":"IL-13R\u03b12\/TGF-\u03b2 bispecific CAR-T cells counter TGF-\u03b2-mediated immune suppression and potentiate anti-tumor responses in glioblastoma","volume":"26","author":"Hou","year":"2024","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.intimp.2026.117134_bb0485","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3390\/biomedicines10071493","article-title":"Alternative CAR therapies: recent approaches in engineering chimeric antigen receptor immune cells to combat Cancer","volume":"10","author":"Moreno","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2026.117134_bb0490","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp2660","article-title":"Next-generation CAR T cell therapies for glioblastoma","volume":"16","author":"Bernstock","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117134_bb0495","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.117134_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114583","article-title":"A general logic-gating framework for CAR-T and nanocarrier cancer therapies: a cross-platform comparative analysis of logic architectures and their molecular implementation strategies","volume":"391","author":"Rehorst","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.intimp.2026.117134_bb0505","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdae173.109","article-title":"IL-3 novel synnotch-car-based t-cell therapy for brain tumors","volume":"6","author":"Okada","year":"2024","journal-title":"Neuro-Oncology Adv."},{"key":"10.1016\/j.intimp.2026.117134_bb0510","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1490911","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-Stevaux","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117134_bb0515","series-title":"Regul. Young Investigator Award Abstracts","first-page":"A317","article-title":"277 SynNotch-CAR T cells demonstrate potent anti-tumor efficacy in a preclinical immunocompetent mouse model for glioblastoma","author":"Lakshmanachetty","year":"2023"},{"key":"10.1016\/j.intimp.2026.117134_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109559","article-title":"Proposing a tandem AND-gate CAR T cell targeting glioblastoma multiforme","volume":"137","author":"Sabahi","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.intimp.2026.117134_bb0525","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ymthe.2018.02.001","article-title":"Adoptive transfer of IL13R\u03b12-specific chimeric antigen receptor T cells creates a pro-inflammatory environment in glioblastoma","volume":"26","author":"Pituch","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.117134_bb0530","doi-asserted-by":"crossref","DOI":"10.3390\/cells13090726","article-title":"A roadmap of CAR-T-cell therapy in glioblastoma: challenges and future perspectives","volume":"13","author":"Montoya","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.117134_bb0535","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.662064","article-title":"CAR T cell-based immunotherapy for the treatment of glioblastoma","volume":"15","author":"Maggs","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.intimp.2026.117134_bb0540","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012308","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions","volume":"13","author":"Walton","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117134_bb0545","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.177141","article-title":"Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment","volume":"9","author":"Hatae","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.intimp.2026.117134_bb0550","first-page":"1","article-title":"Challenges in the treatment of glioblastoma by chimeric antigen receptor T-cell immunotherapy and possible solutions","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117134_bb0555","first-page":"1","article-title":"An update on the clinical trial research of immunotherapy for glioblastoma","volume":"16","author":"Zhou","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117134_bb0560","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12935-025-03944-2","article-title":"Integration of multi-omics approaches in exploring intra-tumoral heterogeneity","volume":"25","author":"Dong","year":"2025","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.intimp.2026.117134_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137174","article-title":"CAR-T cells therapy in glioblastoma: a systematic review on molecular targets and treatment strategies","volume":"25","author":"Agosti","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117134_bb0570","series-title":"Supplementary materials for effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"1","author":"Park","year":"2020"},{"key":"10.1016\/j.intimp.2026.117134_bb0575","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/JCMA.0000000000000302","article-title":"The update of chimeric antigen receptor-T cells therapy in glioblastoma","volume":"83","author":"Chou","year":"2020","journal-title":"J. Chinese Med. Assoc."},{"key":"10.1016\/j.intimp.2026.117134_bb0580","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40164-024-00542-2","article-title":"Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers","volume":"13","author":"Gu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.117134_bb0585","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","article-title":"Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives","volume":"17","author":"Lin","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.117134_bb0590","doi-asserted-by":"crossref","DOI":"10.31083\/j.fbl2809206","article-title":"Present status and advances in chimeric antigen receptor T cell therapy for glioblastoma","volume":"28","author":"Zhou","year":"2023","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.intimp.2026.117134_bb0595","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.trecan.2024.05.007","article-title":"Future perspectives on engineered T cells for cancer","volume":"10","author":"Posey","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.intimp.2026.117134_bb0600","doi-asserted-by":"crossref","first-page":"208","DOI":"10.14791\/btrt.2024.0037","article-title":"Lymphodepletion in chimeric antigen receptor T-cell therapy for solid Tumors: a focus on brain Tumors","volume":"12","author":"Ju","year":"2024","journal-title":"Brain Tumor Res. Treat."},{"key":"10.1016\/j.intimp.2026.117134_bb0605","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.3390\/cancers16162858","article-title":"Strategies for improving CAR T cell persistence in solid Tumors","volume":"16","author":"Wittling","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117134_bb0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2024-010083","article-title":"Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study","volume":"13","author":"Inthanachai","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117134_bb0615","first-page":"1","article-title":"Advanced cell therapies for glioblastoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117134_bb0620","doi-asserted-by":"crossref","unstructured":"T. Eckert, M.S. Zobaer, J. Boulos, A. Alexander-Bryant, T.G. Baker, C. Rivers, A. Das, W.A. Vandergrift, J. Martinez, A. Zukas, S.M. Lindhorst, S. Patel, B. Strickland, N.C. Rowland, Immune resistance in glioblastoma: understanding the barriers to ICI and CAR-T cell therapy, Cancers (Basel) 17 (2025) 1\u201318. doi:https:\/\/doi.org\/10.3390\/cancers17030462.","DOI":"10.3390\/cancers17030462"},{"key":"10.1016\/j.intimp.2026.117134_bb0625","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2612377","article-title":"Oncolytic virus OVV-03 enhances CAR-T cell therapy against glioblastoma via immune modulation and specific HER2 upregulation","volume":"15","author":"Tang","year":"2026","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2026.117134_bb0630","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccell.2022.04.006","article-title":"Regional CAR T cell therapy: an ignition key for systemic immunity in solid tumors","volume":"40","author":"Cherkassky","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.117134_bb0635","article-title":"Focused ultrasound-enhanced cell therapy for brain tumors: summary of roundtable discussions","volume":"8","author":"Padilla","year":"2026","journal-title":"Neuro-Oncol. Adv."},{"key":"10.1016\/j.intimp.2026.117134_bb0640","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12935-022-02687-8","article-title":"Multimodal targeting of glioma with functionalized nanoparticles","volume":"22","author":"Marei","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.intimp.2026.117134_bb0645","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41467-023-37872-4","article-title":"CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy","volume":"14","author":"Chang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117134_bb0650","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.actbio.2020.04.015","article-title":"Nanotechnology and immunoengineering: how nanotechnology can boost CAR-T therapy","volume":"109","author":"Nawaz","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.intimp.2026.117134_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuno.2023.100022","article-title":"Modeling interaction of glioma cells and CAR T-cells considering multiple CAR T-cells bindings","volume":"9","author":"Li","year":"2023","journal-title":"ImmunoInformatics"},{"key":"10.1016\/j.intimp.2026.117134_bb0660","series-title":"Biomaterials promote in vivo generation and immunotherapy of CAR-T cells","first-page":"1","author":"Qin","year":"2023"},{"key":"10.1016\/j.intimp.2026.117134_bb0665","first-page":"1549","article-title":"Enhancing brain entry and therapeutic activity of chimeric antigen receptor T cells with intra-arterial NEO100 in a mouse model of CNS lymphoma","volume":"140","author":"Wang","year":"2024"},{"key":"10.1016\/j.intimp.2026.117134_bb0670","first-page":"1","article-title":"Neuro-oncology advances perillyl alcohol, in adult patients with recurrent","volume":"3","author":"Sch\u00f6nthal","year":"2021"},{"key":"10.1016\/j.intimp.2026.117134_bb0675","first-page":"63","article-title":"Neuro-oncology impermeable therapeutics","volume":"23","author":"Wang","year":"2021"},{"key":"10.1016\/j.intimp.2026.117134_bb0680","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3390\/biomedicines12061230","article-title":"Microbubble-enhanced focused ultrasound for infiltrating gliomas","volume":"12","author":"Seas","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2026.117134_bb0685","series-title":"To go or not to go? Biological logic gating engineered T cells","first-page":"1","author":"Abbott","year":"2022"},{"key":"10.1016\/j.intimp.2026.117134_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mbs.2025.109531","article-title":"CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma","volume":"389","author":"Conte","year":"2025","journal-title":"Math. Biosci."},{"key":"10.1016\/j.intimp.2026.117134_bb0695","first-page":"9","article-title":"Focused ultrasound strategies for brain tumor","volume":"19","author":"Mcdannold","year":"2020"},{"key":"10.1016\/j.intimp.2026.117134_bb0700","series-title":"Graft- versus -host disease risk after chimeric antigen receptor T-cell therapy\u00a0: the diametric opposition of T cells","first-page":"660","author":"Sanber","year":"2021"},{"key":"10.1016\/j.intimp.2026.117134_bb0705","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21217814","article-title":"Investigation of the impact from IL-2, IL-7, and IL-15 on the growth and signaling of activated CD4+ T cells","volume":"21","author":"Coppola","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117134_bb0710","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1186\/s12967-021-03165-x","article-title":"Optimization of metabolism to improve efficacy during CAR-T cell manufacturing","volume":"19","author":"Zhang","year":"2021","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117134_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2026.117134_bb0720","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.21873\/anticanres.14947","article-title":"Development of antigen-specific chimeric antigen receptor KHYG-1 cells for glioblastoma","volume":"41","author":"Kang","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.intimp.2026.117134_bb0725","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.neo.2021.04.005","article-title":"Ultrasound-mediated disruption of the blood tumor barrier for improved therapeutic delivery","volume":"23","author":"Arsiwala","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.intimp.2026.117134_bb0730","series-title":"Control of the activity of CAR T cells within tumours via focused ultrasound","author":"Wu","year":"2022"},{"key":"10.1016\/j.intimp.2026.117134_bb0735","doi-asserted-by":"crossref","unstructured":"Q. Wu, J. Chen, A.E. Berglund, D. Du, R.J. Macaulay, A.B. Etame, The reprogramming impact of SMAC-mimetic on glioblastoma stem cells and the immune tumor microenvironment evolution, J. Exp. Clin. Cancer Res. 44 (2025) 1\u201317. doi:https:\/\/doi.org\/10.1186\/s13046-025-03452-1.","DOI":"10.1186\/s13046-025-03452-1"},{"key":"10.1016\/j.intimp.2026.117134_bb0740","series-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","author":"Choe","year":"2021"},{"key":"10.1016\/j.intimp.2026.117134_bb0745","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.2024024523","article-title":"In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117134_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2026.117134_bb0755","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","article-title":"CAR-T cell combination therapy: the next revolution in cancer treatment","volume":"22","author":"Al-Haideri","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.intimp.2026.117134_bb0760","first-page":"1","article-title":"Overcoming myeloid-driven resistance to CAR T therapy by targeting SPP1","author":"Gholamin","year":"2025","journal-title":"BioRxiv Prepr. Serv. Biol."},{"key":"10.1016\/j.intimp.2026.117134_bb0765","first-page":"1","article-title":"Engineered cytokine signaling to improve CAR T cell effector function","volume":"12","author":"Bell","year":"2021"},{"key":"10.1016\/j.intimp.2026.117134_bb0770","doi-asserted-by":"crossref","first-page":"14324","DOI":"10.3390\/cimb46120859","article-title":"Towards effective treatment of glioblastoma: the role of combination therapies and the potential of phytotherapy and micotherapy","volume":"46","author":"Gaiaschi","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.intimp.2026.117134_bb0775","first-page":"1","article-title":"CAR-T plus radiotherapy: a promising combination for immunosuppressive tumors","volume":"12","author":"Qin","year":"2022"},{"key":"10.1016\/j.intimp.2026.117134_bb0780","doi-asserted-by":"crossref","DOI":"10.1002\/cai2.70018","article-title":"Advances in cellular immune theranostic approaches for glioblastoma: current trends and future directions","volume":"4","author":"Gong","year":"2025","journal-title":"Cancer Innov."},{"key":"10.1016\/j.intimp.2026.117134_bb0785","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.trecan.2024.05.007","article-title":"Future perspectives on engineered T cells for cancer","volume":"10","author":"Posey","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.intimp.2026.117134_bb0790","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.117134_bb0795","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12943-024-02161-1","article-title":"Nanoparticles and bone microenvironment: a comprehensive review for malignant bone tumor diagnosis and treatment","volume":"23","author":"Guan","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.117134_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189033","article-title":"Targeting tumor and bone microenvironment: novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis","volume":"1879","author":"Li","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.intimp.2026.117134_bb0805","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41467-025-68112-6","article-title":"Intrathecal CRISPR-edited allogeneic IL-13R\u03b12 CAR T cells for recurrent high-grade glioma: preclinical characterization and phase I trial","volume":"17","author":"Li","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117134_bb0810","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-026-05497-4","article-title":"Endogenous immune recruitment in glioblastoma CAR T therapy: cytokine, myeloid, and chemokine circuitry","volume":"177","author":"Liu","year":"2026","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.intimp.2026.117134_bb0815","doi-asserted-by":"crossref","DOI":"10.3389\/fphy.2025.1723329","article-title":"Molecular and biophysical remodeling of the blood\u2013brain barrier in glioblastoma: mechanistic drivers of tumor\u2013neurovascular crosstalk","volume":"13","author":"Abikenari","year":"2025","journal-title":"Front. Phys."},{"key":"10.1016\/j.intimp.2026.117134_bb0820","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s44337-025-00405-7","article-title":"Optimizing CAR T-cell therapy for glioblastoma: AI, dose selection, and future directions","volume":"2","author":"Peelay","year":"2025","journal-title":"Discov. Med."},{"key":"10.1016\/j.intimp.2026.117134_bb0825","doi-asserted-by":"crossref","first-page":"9718","DOI":"10.1038\/s41467-024-54129-w","article-title":"Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRP\u03b3-derived CD47 blocker","volume":"15","author":"Martins","year":"2024","journal-title":"Nat. Commun."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692600980X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692600980X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:01:39Z","timestamp":1789142499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692600980X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":158,"alternative-id":["S156757692600980X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117134","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing chimeric antigen receptor T-cell therapy frontiers in glioblastoma: Navigating the current landscape from clinical hurdles to breakthrough strategies","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117134"}}